8 July 2022
EMA/CHMP/617339/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

PROM[1] agenda for the meeting on 11 July 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

11 July 2022, 09:00–16:00, virtual meeting/room 08-A

Disclaimers

Some of the information contained in this document is considered commercially confidential or sensitive and therefore not disclosed.

Of note, agendas and minutes are working documents primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

[1] The CHMP PReparatory and Organisational Matters (PROM) is a meeting to discuss CHMP organisational matters and other topics in preparation for the CHMP Plenary meeting. It is a virtual meeting, which usually takes place on Monday before the CHMP Plenary meeting. CHMP members, working party chairs and national experts together with EMA staff are participating in this forum. Depending on the nature of the issue and availability of documents and experts some PROM topics can be discussed at the CHMP Plenary.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Agenda and Minutes

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of agenda

CHMP PROM agenda for 11 July 2022 meeting

1.3. Adoption of the minutes

CHMP PROM Minutes of 11 July 2022 meeting will be adopted at the July CHMP plenary.

2. Non therapeutic-area-specific working parties

2.1. Patients and Consumers Working Party (PCWP) Healthcare Professionals Working Party (HCPWP)

PCWP: Co-chair: Juan Garcia Burgos (EMA)

HCPWP: Co-chair: Juan Garcia Burgos (EMA)

2.1.1. Agenda and minutes

- Agenda from the PCWP and HCPWP meeting to be held on 22 September 2022
- Minutes from the PCWP and HCPWP meeting held virtually on 1-2 June 2022

Action: for information

2.2. Biologics Working Party (BWP)

Chairs: Sol Ruiz, Sean Barry

2.2.1. Agenda and minutes

- Agenda from the BWP meeting to be held virtually on 11-13 July 2022
- Minutes from the BWP meeting held virtually on 10-12 May 2022

Action: for information

2.3. Quality Working Party (QWP)

Chair: Blanka Hirschlerova

2.3.1. Agenda and minutes

- Final agenda for QWP-CT meeting held virtually on 15 June 2022
- Final minutes for QWP-CT meeting held virtually on 15 June 2022
- Final minutes for QWP meeting held virtually in November 2021

- Final minutes for QWP meeting held virtually in February 2022

Action: for information

2.3.2. Revision of the Guideline on chemistry of active substances: concept paper for public consultation

The report on "Lessons learnt from presence of N-nitrosamine impurities in sartan medicines" (LLE) recognised the need for revision of this guideline. QWP recommends revising the guideline taking into account recommendations from the LLE report as well as learnings from the ongoing 'call for review'. The revision will clarify the requirements for all applications regarding active substances and will bring the guidance up to date with recent developments and knowledge gained on formation of N-nitrosamines and implementation of adequate risk mitigation measures. A three-month public consultation on the concept paper is proposed.

CHMP: Blanka Hirschlerova

Action: for adoption

2.4. Non-clinical Working Party (NcWP)

Chairs: Susanne Brendler-Schwaab, Karen van Malderen

2.4.1. Agenda and minutes

- Draft minutes for NcWP meeting held virtually on 14-15 June 2022
- Draft agenda for NcWP meeting to be held virtually on 12-13 July 2022

Action: For information

2.4.2. Non-clinical Domain 3-year workplan

The 3-year non-clinical domain workplan was endorsed by the Non-clinical domain governance on 7 July.

Action: For adoption

2.4.3. CMDh questions to NcWP on new nitrosamines

- CMDh requests that the NcWP determines the acceptable intake for N-nitrososertraline based on lifetime daily exposure including information on the points of departure and methodology used.
- CMDh requests that the NcWP determines the acceptable intake for N-nitroso-ambroxol based on lifetime daily exposure including information on the points of departure and methodology used.
- CMDh requests that the NcWP determines the acceptable intake for N-nitroso-ramipril based on lifetime daily exposure including information on the methodology used. Based on structural similarity of ACE inhibitors and the fact that N-nitroso-quinapril is currently being assessed by NS-OEG it should be considered to derive a class-specific acceptable intake for ACE inhibitors with similar structural features.

Action: For adoption

2.5. Biosimilar Medicinal Product Working Party (BMWP)

Chair: Elena Wolff-Holz

2.5.1. Agenda and minutes

- Agendas of BMWP meetings held virtually on 30 March 2022 and 1 June 2022
- Final minutes of BMWP meetings held virtually on 2 March 2022, 30 March 2022 and 1 June 2022

Action: For information

2.6. Methodology Working Party (MWP)

Chairs: Kit Roes, Kristin Karlsson

2.6.1. Agenda and minutes

- Final agenda and minutes for MWP meetings held virtually on 16 and 30 June 2022

Action: For information

2.6.2. CHMP question to MWP on the statistical handling of the f2 value

In current guidance the statistical handling of the f2 value is addressed at several places. The most recent one is the PKWP (with BSWP/QWP) Q&A 3.11, where for the bootstrapping method a 90% CI is advised for the assessment of the f2-value.

- The CHMP requests the MWP whether this recommendation of a 90% confidence interval applies also generally in case other methods, if acceptable, are applied.
- The CHMP requests Q&A on this general approach, also outlining how the several places that address the assessment of the f2 value with respect to the statistical confidence level are read together.

Action: for adoption

2.7. Pharmacokinetics Working Party (PKWP)

Chair: Carolien Versantvoort

2.7.1. PKWP request to CVSWP on NTI status of digoxin

Issue of NTI status of digoxin re-discussed by PKWP at virtual meeting on 21 June 2021 in the context of FR request on which parameters to tighten (Cmax, AUC). No recent regulatory precedent could be cited and therefore there is a need for product-specific guidance identified.

Action: For adoption

2.8. Quality Innovation Group (QIG)

2.8.1. Nomination of membership

CHMP is presented with the proposed list of members for the new Quality Innovation Group (QIG) as recommended by the Quality Domain Governance following the implementation of the new working party model. The proposed members cover a wide range of topic areas covering chemical and biological quality (including ATMPs) and GMP compliance. In addition, it is proposed to increase the number of core members from 6 to 8 to cover the expected workload and breadth of topics based on feedback from a recent survey to industry.

Action: For adoption

3. Therapeutic-area-specific working parties and SAGs

3.1. Haematology Working Party (HaemWP)

Chair: Daniela Philadelphy

3.1.1. EC Request for a scientific opinion

- EC request dated June 2022

Action: For discussion

3.2. Central Nervous System Working Party (CNSWP)

No topics

3.3. Cardiovascular Working Party (CVSWP)

No topics

3.4. Infectious Diseases Working Party (IDWP)

No topics

3.5. Oncology Working Party (ONCWP)

Chair: Pierre Demolis

3.5.1. Call for nominations of Vice-Chair for the ONCWP

Following the resignation of Sigrid Klaar as Vice-Chair of the Oncology Working Party (ONCWP) a new call for the position of the Vice-Chair has been launched. The applicants should submit their CV and a letter of motivation by **8 July 2022**.

Election will take place during the July CHMP plenary.

Action: For discussion

3.5.2. Content of 5.1 in Oncology products

Discussion about the type of name of trials to be used doubts about the dataset to be used in phase III trials: primary analysis vs. updated analysis vs. both.

Action: For discussion

3.5.3. Nomination of Oncology ESEC experts

Nomination by ONCWP of an expert to enter the Oncology European Specialised Expert Community (ESEC).

Action: For endorsement

3.5.4. ONCWP Workplan 2022 - 2024

Adoption of the Oncology Working Party 3-year workplan 2022-2024.

Action: For adoption

3.6. Rheumatology/Immunology Working Party (RIWP)

Chair: Romaldas Mačiulaitis

3.6.1. Nominations of the RIWP Vice-chair

Election of RIWP Vice-chair following the implementation of the new Working Parties Operating Model (WOM). Call for nominations was launched among RIWP members on 28 June 2022 with deadline on 07 July 2022. Candidature(s) received.

Election will take place during July CHMP plenary.

Action: For information

3.7. Vaccines Working Party (VWP)

No topics

3.8. Scientific Advisory Groups (SAGs)

No topics

4. Drafting groups

4.1. Excipients Drafting Group

No topics

4.2. Gastroenterology Drafting Group (GDG)

No topics

4.3. Geriatric Expert Group (GEG)

No topics

4.4. Radiopharmaceuticals Drafting Group (RadDG)

No topics

4.5. Respiratory Drafting Group (RDG)

No topics

5. Harmonisation and consistency groups

5.1. International Council on Harmonisation (ICH)

5.1.1. ICH Report to CHMP

In Athens, last June, ICH resumed its regular bi-annual face-to-face meetings. This update intends to cover the state of play for various ICH activities, including its drafting work.

Documents:

- ICH Report to CHMP – Athens 2022

Action: For adoption

- Presentation – ICH Athens 2022

Action: For information

5.1.2. Adoption of guidelines

Following finalisation of the corresponding ICH drafting activities, the following guidelines are brought for CHMP adoption.

- ICH M10 – Bioanalytical method validation, Step 4 final guideline
- ICH M12 – Drug-Drug interactions, Step 2b draft guideline
- ICH Q5A(R2) – Viral safety, Step 2b draft guideline

The ICH M12 and Q5A(R2) draft guideline will be released for a public consultation period of 4 months. For ICH M10, implementation will be set at 6 months after publication on the EMA website after which, the EMA guideline on this topic will be marked as superseded.

Action: For adoption

5.2. Guideline Consistency Group (GCG)

5.2.1. Nomination of the Chair of the GCG

Nomination(s) received.

Action: For adoption

5.3. Summary of product characteristics Advisory Group

No topics

6. Joint groups and collaboration with other Scientific committees

6.1. Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (J 3RsWG)

No topics

6.2. Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)

No topics

6.3. Collaboration with other Scientific committees

6.3.1. PRAC report to CHMP

Chair: Sabine Straus

Summary of recommendations and advice of PRAC meeting held on 4-7 July 2022.

Action: For information

7. Regulatory/Organisational matters

7.1. Regulatory Issues/new legislation

No topics

7.2. CHMP organisation/templates

7.2.1. CHMP learnings

Collection, discussion and recording of CHMP learnings.

CHMP: Outi Mäki-Ikola

Action: For discussion

7.2.2. EMA records management system – update on Sharepoint migration

Introduction of the change, explanation of the impact on the committees' members, the general timeline of migration and how the Committee will be supported throughout the process.

Action: For discussion

7.2.3. Nominations for CHMP co-opted member

The call for nominations for co-opted CHMP members on the on the area of expertise of: **Quality and safety (biological), with expertise in advanced therapies (gene, cell and tissue therapies)** ended on 2 July 2022.

Nomination(s) received.

The appointment will take place during July CHMP plenary.

Action: For information

7.2.4. CHMP Co-rapporteur critique

Experience of the implementation of Co-Rapp Critique in initial marketing authorisation applications.

Action: For discussion

7.2.5. Update on CHMP plenary face-to-face (F2F) meetings

Update on the CHMP plenary F2F/Webex hybrid meetings. Proposed schedule September - December 2022.

Action: For information

7.2.6. PROM Agenda Template

Re-design of the PROM Agenda following the implementation of the Working Party Model.

Action: For adoption

7.2.7. CHMP Workplan 2022

Status report of the activities reflected in the CHMP workplan 2022.

Action: For information

8. Product development support

8.1. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

8.1.1. Appointment of CHMP peer review for SA

Action: For information

8.1.2. Agenda and Table of Decisions

- Agenda from the SAWP meeting that was held virtually on 04-07 July 2022

- Draft table of decisions from the SAWP meeting that was held virtually on 04-07 July 2022

Action: For information

8.1.3. Scientific Advice Working Party (SAWP) call for interest for nomination of replacement SAWP member

Call for interest for nomination of a replacement SAWP member following resignation of Ole Weis Bjerrum (alternate Mogens Westergaard).

Required areas of expertise: Haematology/ onco-haematology, cardiology, biosimilars. Applications should be sent by **29 August 2022**. The new SAWP member and his/her alternate starting date will immediately follow their nomination at the CHMP PROM (5 September 2022).

Action: For information

8.2. Innovation Task Force

8.2.1. ITF meeting

Meeting date: 12 July 2022.

Action: For adoption

8.2.2. ITF meeting

Meeting date: 27 July 2022.

Action: For adoption

8.2.3. ITF meeting

Meeting date: 7 September 2022.

Action: For adoption

9. Product related topics

9.1. Preview CHMP Plenary

CHMP: Harald Enzmann

Action: For information

9.2. COVID-19 ongoing and upcoming procedures

List of currently ongoing and upcoming (imminently, i.e. expected within the next 2 months) applications for COVID-19 vaccines and therapeutics.

Action: For information

9.3. Caprelsa - vandetanib - EMEA/H/C/002315/II/0043

Genzyme Europe BV

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: Letter by the applicant dated 07 July 2022 requesting an extension to the clock stop to respond to the request for supplementary information adopted in May 2022.

Request for Supplementary Information adopted on 19.05.2022, 16.12.2021, 24.06.2021, 28.05.2020.

Action: For adoption

10. Any Other Business

10.1. Rapporteurships

Update.

Action: For information

Appointment of re-examination Rapporteurs for Tuznue/Hervelous – trastuzumab - EMEA/H/C/005066 / EMEA/H/C/005880.

Action: For adoption

10.2. PRIME implementation of 5-year review recommendations

Presentation of the proposals for implementation of the recommendations arising from the first 5 years' experience with the scheme (see also PRIME 5-year report), as discussed and agreed by the PRIME oversight group.

Action: For adoption

10.3. Update on the upcoming proof-of-concept raw data pilot

Update on the proof-of-concept raw data pilot. The pilot, which is expected to start in Q3 2022, will analyse individual patient data in electronic structured format (raw data) from selected marketing authorisation applications. The pilot aims to generate relevant learnings about accessing and analysing raw data during the assessment process. The proof-of-concept raw data pilot is part of EMA's Lifecycle Regulatory Submissions Raw Data project, which is focusing on utilising raw data to support regulatory decision-making and was listed as an action in CHMP's work plan for 2022.

Action: For information

10.4. CHMP Working Parties status'

Introduction and short overview of the new CHMP Working Parties activities by the Working Parties' Chairs and Vice-Chairs or the EMA leads.

- **IDWP** (Infectious Diseases Working Party)
  Chair: Maria Jesus Fernandez Cortizo, Vice-Chair: Maja Sommerfelt Gronvold

- **ONCWP** (Oncology Working Party)
  Chair: Pierre Demolis
- **NCWP** (Non-Clinical Working Party)
  Chair: Susanne Brendler-Schwaab, Vice-Chair: Karen van Malderen
- **MWP** (Methodology Working Party)
  Chair: Kit Roes, Vice-Chair: Kristin Karlsson
- **CVSWP** (Cardiovascular Working Party)
  Chair: Alar Irs, Vice-Chair: Patrick Vrijlandt
- **CNSWP** (Central Nervous System Working Party)
  Chair: Andre Elferink
- **HAEMWP** (Haematology Working Party)
  Chair: Daniela Philadelphy
- **RIWP** (Rheumatology/Immunology Working Party)
  Chair: Romaldas Mačiulaitis
- **VWP** (Vaccines Working Party)
  Chair: Mair Powell
- **BMWP** (Biosimilar Medicinal Product Working Party)
  Chair: Elena Wolf Holz
- **BWP** (Biologics Working Party)
  Chair: Sol Ruiz, Vice-Chair: Sean Barry
- **QWP** (Quality Working Party)
  Chair: Blanka Hirschlerova

CHMP: Harald Enzmann

Action: For information

10.5. Improvement of worksharing for type IB variations – centralised procedure

Similar to the improvements agreed by the CMDh for type IB worksharing procedures handled by the NCA's for nationally authorised products, EMA proposes to implement a weekly start 30-day timetable for type IB work sharing variations for medicines authorised by the centralised procedure.

Action: For adoption

10.6. Outcome of CHMP Pilot on early dialogue with patient organisations

Presentation of the results of the pilot (Jan 2021 – May 2022) which reached out to patient organisations for their insights at the beginning of new orphan MAAs. Results from questionnaires completed by Rapporteurs/Co-Rapporteurs to be discussed and way forward decided.

Action: For discussion

10.7. Update on enhanced communication with down-stream decision makers about regulatory assessment

Presentation of the 3-year experience review (2017 – 2020) on the webinars between EMA, CHMP Rapporteurs and HTA bodies to optimise the regulatory assessment report as reference for down-stream decision making by HTA bodies.

Action: For information